PAR 1.96% 25.0¢ paradigm biopharmaceuticals limited..

Short term price action isn't looking good. Support line broken...

  1. 60 Posts.
    lightbulb Created with Sketch. 10
    Short term price action isn't looking good. Support line broken and looks to be trending down sub $2 pending positive news from the FDA. If there is more than just a 'covid delay' and the FDA wants more information on the non clinical data or even restructure of trials I can see this going sub $1.50. Good buying op as eventually the phase 3 trial will begin (even if delayed) and we should see it back to $3.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.